XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenues (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:

			Three months ended September 30,																		Nine months ended September 30,
			2018						2017						2018						2017
Products:
Acetadote			$	1,122,544					$	1,342,457					$	3,238,284					$	4,331,675
Omeclamox-Pak			278,017						190,835						509,358						1,213,635
Kristalose			3,017,803						2,749,966						9,490,901						8,037,994
Vaprisol			(67,436)						385,541						1,712,353						1,346,793
Caldolor			1,318,109						896,640						3,458,881						2,762,790
Ethyol			2,593,830						2,566,611						7,659,594						8,325,254
Totect			45,249						2,916,425						727,211						2,916,425
Other			184,414						148,486						447,277						566,277
Total net revenues			$	8,492,530					$	11,196,961					$	27,243,859					$	29,500,843

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration